What is IOVA stock price today?

IOVA (Iovance Biotherapeutics Inc) stock is trading at $3.46 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IOVA stock going up or down today?

IOVA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IOVA stock now?

The decision to buy IOVA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IOVA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IOVA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IOVA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IOVA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IOVA's P/E ratio?

P/E ratio data for IOVA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IOVA's market cap?

IOVA (Iovance Biotherapeutics Inc) has a market capitalization of $1.52 billion, making it a small-cap stock.

What is IOVA's price to book ratio?

IOVA trades at a price-to-book (P/B) ratio of 2.18, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IOVA pay dividends?

IOVA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IOVA's dividend yield?

IOVA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IOVA stock a good long-term investment?

IOVA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IOVA's revenue growth rate?

IOVA has shown revenue growth of 0.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

IOVA is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in IOVA?

Key risks for IOVA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IOVA compare to its competitors?

Compare IOVA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IOVA's performance and positioning.

What is IOVA's stock price target for 2026?

Our AI model provides price targets for IOVA based on fundamental analysis: Bull case $4.50 (+30%), Base case $3.98 (+15%), Bear case $3.11 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IOVA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IOVA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IOVA's next earnings report?

IOVA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IOVA - Iovance Biotherapeutics Inc

NYSE * Health Care * Biotechnology

$3.46

$-0.24 (-6.49%)

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Key Statistics

Market Cap

$1.52B

P/B Ratio

2.18

EPS

$-1.09

Revenue Growth

+0.2%

Profit Margin

-1.5%

Employees

975

How IOVA Compares to Peers

IOVA has the fastest revenue growth among competitors

IOVA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IOVA(This stock)	$1.52B	N/A	0%	-1.5%	-
AMGNAmgen Inc	$188.58B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.56B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$111.93B	28.7	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.92B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.88B	20.1	-0%	0.1%	vs BIIB

Iovance Biotherapeutics Inc Company Information

Headquarters: California; U.S.A
Website: www.iovance.com
Sector: Health Care
Industry: Biotechnology

IOVA - Iovance Biotherapeutics Inc

About Iovance Biotherapeutics Inc

IOVA Key Statistics

How IOVA Compares to Peers

Iovance Biotherapeutics Inc Company Information

IOVA Lician Score

IOVA Financial Snowflake

Upcoming Events for IOVA